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Study of Inflammatory Bowel Disease (IOIBD) has undertaken a RAND 
panel of expert opinion regarding the care of IBD patients during 
the COVID-19 pandemic.9 In time the evidence to support clinical 
recommendations is likely to develop. Others from epicentres of 
the COVID-19 pandemic have also given specific recommendations 
based on their experience.10
The paper by King et al reminds us of two important and interact-
ing challenges facing IBD clinicians in the future. First, we will continue 
to see more IBD as the prevalence increases worldwide. This will re-
quire improved management strategies to provide high-quality care to 
more patients. Second, complications of the disease and its treatment, 
be they established or evolving will require individualised approaches. 
While some planning will be needed to mitigate these, working to-
gether at times of crisis will enable the best results for our patients.
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Editorial: increasing IBD prevalence and its complications in the 
context of the COVID-19 pandemic. Authors' reply
Benson-Pope et al have highlighted the concerns that many patients 
with IBD, along with their medical teams, face during the coronavirus 
pandemic.1 Immunosuppression has been the mainstay of moderate 
to severe IBD management for decades. With large IBD populations 
around the world, the need to protect such potentially vulnerable 
patients from coronavirus disease 2019 (COVID-19) is vital.
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The novelty of COVID-19 has thrown up many challenges for 
the clinician, including how best to manage medications and what 
new onset symptoms may mean, given that COVID-19 can cause di-
arrhoea and abdominal pain, and that viral illnesses can lead to IBD 
flares.2,3 Although no evidence currently suggests that COVID-19 
can induce flares in IBD, avoidance of COVID-19 in IBD, especially 
in those who are immunosuppressed or have active disease, is cru-
cial. Benson-Pope et al, have highlighted the consensus statements 
from the International Organisation for the study of Inflammatory 
Bowel Disease (IOIBD) concerning IBD medication and COVID-19; 
however, a degree of disagreement exemplifies the lack of knowl-
edge and a degree of uncertainty concerning how best to manage 
patients.4 Several national and international societies and charities 
have given advice on IBD and COVID-19 and many governments 
have been clear on the need for social distancing.5-8
Given the increasing prevalence of IBD, not only patients but 
also many healthcare professionals will be living with IBD.9 With 
health systems around the world coming under strain, adequate 
personal protective equipment may not always be readily avail-
able to healthcare professionals with IBD. With out-patient ap-
pointments and monitoring being postponed, IBD medical teams 
and patients must be alert to the evolving guidance and take all 
necessary precautions in the very different healthcare environ-
ment we now all work in.
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